Exclusive Summary

• Mechanism Innovation & High Selectivity (Best-in-class potential): Utilizes long-acting siRNA to highly specifically silence MUC5AC (IC50 of 0.015nM, 90% maximal inhibition) which causes pathological mucus obstruction, while completely sparing MUC5B which is essential for normal airway physiological functions, demonstrating a superior safety profile over competitors.
• Innovative Long-acting Inhalable Delivery: Employs a direct-to-lung inhaler formulation combined with long-acting technology (Q2M), promising to completely disrupt the daily-dosing reliance of traditional respiratory treatments and significantly boost patient compliance.
• Addressing Massive Unmet Market Needs: Directly targets the critical unmet need in huge COPD and NCFB markets where existing standard-of-care therapies universally fail to effectively halt disease progression caused by mucus hypersecretion.
• Flexible Early-stage Partnering Opportunity: Currently in the early IND-Enabling development stage with breakthrough data in human bronchial organoids and ongoing large animal validation, presenting a highly cost-effective entry point for overseas pharma partners to acquire and lead global clinical development.

Asset Materials

Contact Us for Full Materials